Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study

---

Pernas S., Hinojo C., Pascual J., AKSOY S., Clack G., McIntosh S.

Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Country: ELECTR NETWORK
• Hacettepe University Affiliated: No